selinexor multiple myeloma
Selected indexed studies
- Selinexor in multiple myeloma. (Expert Opin Pharmacother, 2024) [PMID:38503547]
- Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas. (Curr Opin Oncol, 2022) [PMID:35880450]
- Selinexor in relapsed/refractory multiple myeloma. (Ther Adv Hematol, 2020) [PMID:32566115]
_Worker-drafted node — pending editorial review._
Connections
selinexor multiple myeloma is a side effect of
Sources
- Selinexor-Bortezomib-Dexamethasone: A Review in Previously Treated Multiple Myeloma. (2023) pubmed
- Selinexor in multiple myeloma. (2024) pubmed
- Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial. (2020) pubmed
- Selinexor in relapsed/refractory multiple myeloma. (2020) pubmed
- Oral Selinexor-Dexamethasone for Triple-Class Refractory Multiple Myeloma. (2019) pubmed
- Selinexor therapy for multiple myeloma and non-Hodgkin lymphomas. (2022) pubmed
- Selinexor for multiple myeloma. (2022) pubmed
- Treatment of multiple myeloma with selinexor: a review. (2024) pubmed
- Selinexor for the treatment of multiple myeloma. (2020) pubmed
- Selinexor: Targeting a novel pathway in multiple myeloma. (2023) pubmed